Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | TNKS | O95271 | 3/20 | 0.54 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.51 |
| ▸ | FEN1 | P39748 | 1/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.51 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10212480 | 0.97 | KDM4E (0.55) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL29087625 | 0.89 | KDM4E (0.52) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL8832123 | 0.85 | KDM4E (0.49) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL6948237 | 0.85 | TSHR (0.50) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5886053 | 0.85 | TNKS (0.43) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL15958955 | 0.84 | PARP1 (0.47) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL696548 | 0.84 | DHODH (0.56) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL25433684 | 0.81 | SCN1A (0.43) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5970052 | 0.81 | TSHR (0.55) | KDM4ESMN1; SMN2ALDH1A1LMNATDP1 | |
| SCHEMBL3579908 | 0.81 | PARP1 (0.61) | KDM4ESMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104356170-B | Ruthenium iridium heteronuclear ring metal compound, and preparation method and application thereof | 洛阳师范学院 | 2017-02-15 | — | — | CN | disclosed |
| CN-105392498-A | Anti-malignant tumor agent composition | PHARMA CO LTD J | 2016-03-09 | — | — | CN | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | disclosed |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | disclosed |
| US-8741887-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-03 | — | — | US | disclosed |
| US-8722658-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-13 | — | — | US | disclosed |
| US-8722658-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-13 | — | — | US | disclosed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| CN-1293042-C | Aromatic amino acid derivative and pharmaceutical composition thereof | HITOSHI ENDOU (JP) | 2007-01-03 | — | — | CN | disclosed |
| CN-1630632-A | Aromatic amino acid derivative and pharmaceutical composition thereof | HITOSHI ENDOU (JP) | 2005-06-22 | — | — | CN | disclosed |
| CN-1159007-C | Benzimidazole compounds | ť��˹����ѧ����Ͷ������˾ | 2004-07-28 | — | — | CN | disclosed |
| EP-0841924-B1 | BENZIMIDAZOLE COMPOUNDS | UNIV NEWCASTLE VENTURES LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| US-6310082-B1 | PHARMACEUTICAL COMPOSITION COMPRISING EFFECTIVE POLY(ADP-RIBOSE)POLYMERASE ENZYME INHIBITING AMOUNT OF BENZIMIDAZOLE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT AND/OR PRO-DRUG FORM THEREOF, WITH ACCEPTABLE CARRIER | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6100283-A | PRODRUG PHOSPHATE DERIVATIVE FOR POLY (ADP-RIBOSE) POLYMERASE ENZYME INHIBITOR FOR ADMINISTERING IN CONJUNCTION WITH ANTITUMOR DRUG OR RADIOTHERAPY | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2000-08-08 | — | — | US | disclosed |
| CN-1195985-A | Benzimidazole compounds | UNIV NEWCASTLE VENTURES LTD (GB) | 1998-10-14 | — | — | CN | disclosed |
| EP-0841924-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997004771-A1 | BENZIMIDAZOLE COMPOUNDS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | KDM4E 1931/4885SMN1; SMN2 1895/4885NPC1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.